Form 4: Intra-Cellular Therapies CEO Sharon Mates Disposes of Shares and Options Following Merger with Johnson & Johnson

Following the merger of Intra-Cellular Therapies with Johnson & Johnson, CEO Sharon Mates reports the disposal of shares and derivative securities as per the merger agreement.

Summary

• Sharon Mates, CEO of Intra-Cellular Therapies, filed a Form 4 on April 2, 2025, reporting changes in beneficial ownership of securities.
• The filing is related to the merger between Intra-Cellular Therapies and Johnson & Johnson, which became effective on April 2, 2025.
• As a result of the merger, Intra-Cellular Therapies became a wholly-owned subsidiary of Johnson & Johnson.
• Mates disposed of 945,235 directly held common stock shares and 190,000 indirectly held shares through the Sharon Mates Family Foundation at a price of $132 per share.
• Outstanding stock options with an exercise price less than $132 were canceled and converted into the right to receive cash equal to the difference between $132 and the exercise price.
• Stock options with an exercise price equal to or exceeding $132 were canceled for no consideration.
• Restricted Stock Units (RSUs) were canceled and converted into the right to receive $132 per share, with some RSUs granted in 2025 payable at the original vesting date.
• Performance Stock Units (PRSUs) were canceled and converted into the right to receive $132 per share, assuming target performance levels were met.

Sentiment

Score: 7

Explanation: The document reflects the completion of a merger, which is generally a positive event for shareholders who receive a cash payout. The sentiment is neutral to positive as it represents the conclusion of a significant corporate event.

Positives

• Shareholders received $132 per share in cash as a result of the merger.
• Option holders with in-the-money options received cash for the difference between the merger consideration and the exercise price.

Negatives

• Existing shareholders no longer own shares in Intra-Cellular Therapies as it is now a wholly-owned subsidiary of Johnson & Johnson.
• Out-of-the-money options were canceled for no consideration.

Future Outlook

The document does not contain specific forward-looking statements beyond the completion of the merger.

Industry Context

The acquisition of Intra-Cellular Therapies by Johnson & Johnson reflects a trend of larger pharmaceutical companies acquiring smaller biotech firms with promising drug candidates or approved treatments. This allows larger companies to expand their portfolios and pipelines while providing smaller companies with the resources and infrastructure for broader commercialization.

Comparison to Industry Standards

• The acquisition price of $132 per share is a key metric to compare against other acquisitions in the biopharmaceutical industry.
• Comparable transactions could include the acquisition of Alexion Pharmaceuticals by AstraZeneca or the acquisition of Biohaven Pharmaceutical Holding Company by Pfizer.
• The premium paid over Intra-Cellular Therapies' pre-announcement stock price would be compared to the average premium paid in similar biotech acquisitions to assess the deal's value for shareholders.

Stakeholder Impact

• Shareholders received $132 per share in cash.
• Employees of Intra-Cellular Therapies now work for a subsidiary of Johnson & Johnson, which may bring changes in company culture and opportunities.
• The merger could impact the availability and development of Intra-Cellular Therapies' drugs.

Key Dates

Keywords

Merger, Intra-Cellular Therapies, Johnson & Johnson, Sharon Mates, Form 4, Securities, Stock Options, RSU, PRSU, Beneficial Ownership